Biovicas DiviTumTKa visar starka resultat vid malignt melanom

20 maj 2021 - Biovica, aktivt inom cancerdiagnostik, meddelar idag att DiviTumTKa visar prognostisk och prediktiv förmåga hos patienter med spridd hudcancer som genomgår immunterapi. Dessa resultat från en ny studie vid Karolinska universitetssjukhuset kommer att presenteras vid ASCOs årsmöte 4-8 juni 2021.

2021-05-20T06:00:00+02:00May 20th, 2021 06:00|

Biovica’s DiviTumTKa shows strong capabilities in malignant melanoma

May 20, 2021 - Biovica, active in cancer diagnostics, today announces that DiviTumTKa shows prognostic and predictive capabilities in metastatic cutaneous melanoma patients undergoing immunotherapy. These results from a new study at Karolinska University Hospital will be presented at the upcoming ASCO annual meeting, June 4-8, 2021.

2021-05-20T06:00:00+02:00May 20th, 2021 06:00|

Biovica strengthens the management team

Biovica, active in cancer diagnostics, today announced that the company has strengthened the management team with Helle Fisker as new commercial manager and Joakim Arwidson as new quality and regulatory manager.

2021-05-07T10:36:24+02:00April 29th, 2021 09:00|

Biovica förstärker ledningsgruppen

Biovica, verksamt inom cancerdiagnostik, meddelade idag att bolaget har förstärkt ledningsgruppen med Helle Fisker som ny kommersiell chef och Joakim Arwidson som ny kvalitets- och regulatorisk chef.

2021-04-29T09:00:00+02:00April 29th, 2021 09:00|

DiviTum®TKa budget impact model results show potential for savings in cost of care

Biovica, active in cancer diagnostics, today announced that the results from a budget impact model of monitoring with DiviTum®TKa can give savings of up to three times the extra spend relative to current management. The results will be presented at the leading health economics and outcomes research conference, ISPOR 2021 in May.

2021-04-23T06:30:00+02:00April 23rd, 2021 06:30|